• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax).
【24h】

Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax).

机译：二琥珀酸虾青素二钠衍生物（Cardax）对心脏的保护和心肌保护作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cardioprotection in humans by carotenoids has been inferred from observational and epidemiologic studies, however, direct studies of cardioprotection and myocardial salvage by carotenoids are lacking. In the current study, intravenous (I.V.) pre-treatment with a novel carotenoid derivative (disodium disuccinate astaxanthin; Cardax) was evaluated as a myocardial salvage agent in a Sprague-Dawley rat infarct model. Animals were dosed once per day I.V. by tail vein injection for 4 days at one of 3 doses (25, 50, and 75 mg/kg) prior to the infarct study carried out on day 5. The results were compared with control animals treated with saline vehicle. Thirty (30) minutes of occlusion of the left anterior descending (LAD) coronary artery was followed by 2 hours of reperfusion prior to sacrifice, a regimen which resulted in a mean infarct size (IS) as a percent (%) of the area at risk (AAR) of 59 +/- 3%. Area at risk was quantified by Patent blue dye injection, and infarct size (IS) was determined by triphenyltetrazolium chloride (TTC) staining. Cardax at 50 and 75 mg/kg for 4 days resulted in a significant mean reduction in IS/AAR to 35 +/- 3% (41% salvage) and 26 +/- 2% (56% salvage), respectively. Infarct size and myocardial salvage were significantly, and linearly, correlated with plasma levels of non-esterified, free astaxanthin at the end of reperfusion. These results suggest that parenteral Cardax may find utility in those clinical applications where pre-treatment of patients at risk for myocardial infarction is performed.
机译：从观察和流行病学研究可以推断出类胡萝卜素对人的心脏保护作用，但是，缺乏对类胡萝卜素对心脏保护作用和心肌拯救作用的直接研究。在当前的研究中，在Sprague-Dawley大鼠梗塞模型中，使用新型类胡萝卜素衍生物（二琥珀酸二异丁酯虾青素; Cardax）进行的静脉内（IV）预处理被评估为心肌挽救剂。每天给动物静脉内给药一次。在第5天进行梗塞研究之前，先以3种剂量（25、50和75 mg / kg）之一进行尾静脉注射4天，然后将结果与用生理盐水处理的对照动物进行比较。在处死前，将左前降支（LAD）冠状动脉闭塞三十（30）分钟，然后再灌注2小时，该方案导致平均梗塞面积（IS）占面积的百分比（％）风险（AAR）为59 +/- 3％。危险区域通过专利蓝色染料注射进行定量，梗塞面积（IS）通过三苯基氯化四氮唑（TTC）染色确定。以50和75 mg / kg的Cardax处理4天后，IS / AAR的平均均值显着降低，分别降至35 +/- 3％（41％残存率）和26 +/- 2％（56％残存率）。在再灌注结束时，梗塞面积和心肌抢救率与血浆中未酯化的游离虾青素的血浆含量呈显着线性相关。这些结果表明，非肠道Cardax可能在对有心肌梗塞危险的患者进行预处理的临床应用中找到用处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号